Market Cap 9.31M
Revenue (ttm) 0.00
Net Income (ttm) -29.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.19
Volume 97,500
Avg Vol 291,684
Day's Range N/A - N/A
Shares Out 15.74M
Stochastic %K 67%
Beta 0.85
Analysts Strong Sell
Price Target $10.33

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 5500
Address:
505 Coast Boulevard South, Suite 307, La Jolla, United States
MUBSN
MUBSN May. 12 at 7:15 PM
$CALC what a pipeline!!
0 · Reply
Nousernam3
Nousernam3 May. 12 at 6:22 PM
$CALC in for a đź’Ż
0 · Reply
keokeostwiz
keokeostwiz May. 12 at 3:56 PM
$CALC Auxora P2b results establishing a strong foundation toward filling the void in AP and AKI unmet medical need areas critical in providing therapy to patients suffering from pancreatitis and kidney disease....the immediate targets for the company are FDA acceptance of P3 trial design and financing.....with positive P2b results supporting a strong clinical resume these objectives should be achieved in the second quarter setting the stage for the balance of 2026 success......JMO
1 · Reply
66Caprice327
66Caprice327 May. 12 at 11:49 AM
$CALC Let her buck…
0 · Reply
ye81
ye81 May. 12 at 11:12 AM
$CALC https://finance.yahoo.com/sectors/healthcare/articles/calcimedica-reports-first-quarter-2026-110000015.html
0 · Reply
Action80gr
Action80gr May. 12 at 9:20 AM
$CALC Severe Hantavirus cases involve hyperinflammation, vascular leak & pulmonary edema — interesting overlap with Auxora’s CRAC inhibition mechanism. Not saying pipeline expansion, but scientifically worth watching given prior ARDS/acute lung injury focus. Could this be a future platform opportunity? $CALC
0 · Reply
MUBSN
MUBSN May. 9 at 1:31 PM
0 · Reply
MUBSN
MUBSN May. 9 at 1:30 PM
1 · Reply
MUBSN
MUBSN May. 9 at 1:28 PM
0 · Reply
keokeostwiz
keokeostwiz May. 8 at 8:12 PM
$CALC Only 57.5K shares traded today as very little sell pressure coupled with small appetite to hit the ask.....shares will be difficult to acquire under these conditions setting the stage for a news break and quick acceleration......next week should be interesting if ER debuts some new info as the silence here has been deafening and due a shakeup.....JMO
2 · Reply
Latest News on CALC
CalciMedica price target lowered to $10 from $20 at Oppenheimer

2026-03-05T13:27:54.000Z - 2 months ago

CalciMedica price target lowered to $10 from $20 at Oppenheimer


CalciMedica files $125M mixed securities shelf

2026-03-03T22:00:59.000Z - 2 months ago

CalciMedica files $125M mixed securities shelf


CalciMedica downgraded to Neutral from Buy at H.C. Wainwright

2026-01-29T11:11:18.000Z - 3 months ago

CalciMedica downgraded to Neutral from Buy at H.C. Wainwright


CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 5, 2025, 7:00 AM EST - 1 year ago

CalciMedica Secures Credit Facility for Up to $32.5 Million


CalciMedica Set to Join Russell Microcap® Index

Jul 1, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Set to Join Russell Microcap® Index


MUBSN
MUBSN May. 12 at 7:15 PM
$CALC what a pipeline!!
0 · Reply
Nousernam3
Nousernam3 May. 12 at 6:22 PM
$CALC in for a đź’Ż
0 · Reply
keokeostwiz
keokeostwiz May. 12 at 3:56 PM
$CALC Auxora P2b results establishing a strong foundation toward filling the void in AP and AKI unmet medical need areas critical in providing therapy to patients suffering from pancreatitis and kidney disease....the immediate targets for the company are FDA acceptance of P3 trial design and financing.....with positive P2b results supporting a strong clinical resume these objectives should be achieved in the second quarter setting the stage for the balance of 2026 success......JMO
1 · Reply
66Caprice327
66Caprice327 May. 12 at 11:49 AM
$CALC Let her buck…
0 · Reply
ye81
ye81 May. 12 at 11:12 AM
$CALC https://finance.yahoo.com/sectors/healthcare/articles/calcimedica-reports-first-quarter-2026-110000015.html
0 · Reply
Action80gr
Action80gr May. 12 at 9:20 AM
$CALC Severe Hantavirus cases involve hyperinflammation, vascular leak & pulmonary edema — interesting overlap with Auxora’s CRAC inhibition mechanism. Not saying pipeline expansion, but scientifically worth watching given prior ARDS/acute lung injury focus. Could this be a future platform opportunity? $CALC
0 · Reply
MUBSN
MUBSN May. 9 at 1:31 PM
0 · Reply
MUBSN
MUBSN May. 9 at 1:30 PM
1 · Reply
MUBSN
MUBSN May. 9 at 1:28 PM
0 · Reply
keokeostwiz
keokeostwiz May. 8 at 8:12 PM
$CALC Only 57.5K shares traded today as very little sell pressure coupled with small appetite to hit the ask.....shares will be difficult to acquire under these conditions setting the stage for a news break and quick acceleration......next week should be interesting if ER debuts some new info as the silence here has been deafening and due a shakeup.....JMO
2 · Reply
MUBSN
MUBSN May. 8 at 7:58 PM
$CALC Auxora as a potencial candidate for hantavirus treatment?
0 · Reply
pablo4
pablo4 May. 7 at 6:01 PM
$CALC looking pretty good on a very lousy day in biotech land....see XBI.
0 · Reply
66Caprice327
66Caprice327 May. 7 at 3:34 PM
$CALC No material news. No selling. No liquidity. Easy hold.
0 · Reply
66Caprice327
66Caprice327 May. 6 at 9:04 PM
$CALC I reiterate.
1 · Reply
keokeostwiz
keokeostwiz May. 6 at 7:20 PM
$CALC Perfect storm forming with AUXORA efficacy.....P3 design acceptance forthcoming.....FDA streamlining NDA applications....incorporating AI in processing results....all assets signaling expedited approval and much needed relief for acute pancreatitis patients....a game changer for little CALC......JMO
0 · Reply
keokeostwiz
keokeostwiz May. 5 at 5:44 PM
$CALC January price 7.20 Analyst PT 20......false safety allegations....April price .46 Analyst PT 10.....partison toward price moving toward 10 by end of the year.......JMO
0 · Reply
keokeostwiz
keokeostwiz May. 5 at 2:10 AM
$CALC Reread the P2b Auxora results and the findings were so outstanding decided to keep adding everyday this stays under .60….do not understand the price disconnect relative to exciting results…with the FDA implementing a streamlines approach to NDA approval and CALC utilizing AI in trial procedures expecting only good encouraging news as P3 proceeds…difficult to ignore the equation unfolding and can even foresee a buyer appearing on the horizon….exciting times for CALC…….JMO
1 · Reply
shoemaker74
shoemaker74 May. 4 at 2:35 PM
$CALC Nice climb, any good news?
1 · Reply
SUGONDEEZNUTS
SUGONDEEZNUTS May. 1 at 5:17 PM
$CALC 10-K/A filed yesterday.
1 · Reply
keokeostwiz
keokeostwiz May. 1 at 3:31 PM
$CALC Volume surge from 21.7 to 74.9 in 10 minutes....good to see some interest ....watching for contagion continuation today.....GL
0 · Reply
keokeostwiz
keokeostwiz Apr. 30 at 3:32 PM
$CALC Using this period of price suppression to add shares before the sand in this hour glass vanishes in a blink of an eye.....JMO
0 · Reply
Super_Marioo
Super_Marioo Apr. 30 at 3:05 PM
$CALC -unbelievable that we are still trading down here. only reason I can think of is a big whale is keeping it down and wants a direct offering down here before we pop.
1 · Reply